|
顯示項目 655311-655335 / 2312640 (共92506頁)
<< < 26208 26209 26210 26211 26212 26213 26214 26215 26216 26217 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2006-11 |
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
|
Shiah, HS; Chao, Y; Chen, LT; Yao, TJ; Huang, JD; Chang, JY; Chen, PJ; Chuang, TR; Chin, YH; Whang-Peng, J; Liu, TW |
| 國立臺灣大學 |
2006 |
Phase I and Pharmacokinetic Study of Oral Thalidomide in Patients with Advanced Hepatocellular Carcinoma
|
趙毅; 陳立宗; 黃金鼎; 張俊彥; 陳培哲; 金詠興; 彭汪嘉康; 劉滄梧; CHAO, YEE; CHEN, LI-TZONG; HUANG, JIN-DING; CHANG, JANG-YANG; CHEN, PEI-JER; CHIN, YUNG-HSIN; WHANG-PENG, JACQUELINE; LIU, TSANG-WU |
| 國立臺灣大學 |
2006-11 |
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
|
Shiah, HS (Shiah, Her-Shyong); Chao, Y (Chao, Yee); Chen, LT (Chen, Li-Tzong); Yao, TJ (Yao, Tzy-Jyun); Huang, JD (Huang, Jin-Ding); Chang, JY (Chang |
| 臺大學術典藏 |
2021-07-03T03:35:20Z |
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
|
Shiah H.-S.; Chao Y.; Chen L.-T.; Yao T.-J.; Huang J.-D.; Chang J.-Y.; PEI-JER CHEN; Chuang T.-R.; Chin Y.-H.; Whang-Peng J.; Liu T.-W. |
| 臺大學術典藏 |
2018-09-10T03:53:01Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen, A.-L. and Hsu, C.-H. and Lin, J.-K. and Hsu, M.-M. and Ho, Y.-F. and She, T.-S. and Ko, J.-Y. and Lin, J.-T. and Lin, B.-R. and Wu, M.-S. and Yu, H.-S. and Jee, S.-H. and Chen, G.-S. and Chen, T.-M. and Chen, C.-A. and Lai, M.-K. and Pu, Y.-S. and Pan, M.-H. and Wang, Y.-J. and Tsai, C.-C. and Hsieh, C.-Y.; CHI-AN CHEN |
| 臺大學術典藏 |
2018-09-10T03:51:09Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen, A.-L.;Hsu, C.-H.;Lin, J.-K.;Hsu, M.-M.;Ho, Y.-F.;She, T.-S.;Ko, J.-Y.;Lin, J.-T.;Lin, B.-R.;Wu, M.-S.;Yu, H.-S.;Jee, S.-H.;Chen, G.-S.;Chen, T.-M.;Chen, C.-A.;Lai, M.-K.;Pu, Y.-S.;Pan, M.-H.;Wang, Y.-J.;Tsai, C.-C.;Hsieh, C.-Y.; SHIOU-HWA JEE |
| 臺大學術典藏 |
2018-09-10T03:49:28Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
MING-SHIOU WU; Chen, A.-L. and Hsu, C.-H. and Lin, J.-K. and Hsu, M.-M. and Ho, Y.-F. and She, T.-S. and Ko, J.-Y. and Lin, J.-T. and Lin, B.-R. and Wu, M.-S. and Yu, H.-S. and Jee, S.-H. and Chen, G.-S. and Chen, T.-M. and Chen, C.-A. and Lai, M.-K. and Pu, Y.-S. and Pan, M.-H. and Wang, Y.-J. and Tsai, C.-C. and Hsieh, C.-Y. |
| 臺大學術典藏 |
2018-09-10T03:44:41Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
MIN-HSIUNG PAN; MIN-HSIUNG PAN |
| 臺大學術典藏 |
2018-09-10T03:42:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen, A.-L.;Hsu, C.-H.;Lin, J.-K.;Hsu, M.-M.;Ho, Y.-F.;She, T.-S.;Ko, J.-Y.;Lin, J.-T.;Lin, B.-R.;Wu, M.-S.;Yu, H.-S.;Jee, S.-H.;Chen, G.-S.;Chen, T.-M.;Chen, C.-A.;Lai, M.-K.;Pu, Y.-S.;Pan, M.-H.;Wang, Y.-J.;Tsai, C.-C.;Hsieh, C.-Y.; YUNN-FANG HO |
| 國立臺灣大學 |
2001 |
Phase I Clinical Trial of Curcumin, a Chemopreventive Agent, in Patients with High-Risk or Pre-Malignant Lesions
|
鄭安理; 徐志宏; 林仁混; 徐茂銘; 沈宗憲; 何藴芳; 柯政郁; 林肇堂; 吳明賢; 紀秀華; CHENG, ANN-LII; HSU, CHIH-HUNG; LIN, JEN-KUN; HSU, MOW-MING; SHEEN, TZUNG-SHIAHN; HO, YUNN-FANG; KO, JENQ-YUH; LIN, JAW-TOWN; WU, MING-SHIANG; JEE, SHIOU-HWA |
| 臺大學術典藏 |
2020-01-22T07:50:53Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; CHI-AN CHEN; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y.; Lin J.-K.; Hsu C.-H.; Chen A.-L.; Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chi-An Chen;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y. |
| 臺大學術典藏 |
2020-04-28T07:25:39Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y.; Lin B.-R.; Lin J.-T.; Ko J.-Y.; She T.-S.; Ho Y.-F.; CHIH-HUNG HSU; Lin J.-K.; Hsu M.-M.; Chen A.-L.; Chen A.-L.;Chih-Hung Hsu;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y. |
| 臺大學術典藏 |
2020-11-02T02:05:31Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Hsieh C.-Y.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Ho Y.-F.; Hsu M.-M.; Lin J.-K.; Hsu C.-H.; Chen A.-L. |
| 臺大學術典藏 |
2020-11-27T08:14:40Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Chang-Yao Hsieh; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Yeong-Shiau Pu;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y.; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; YEONG-SHIAU PU; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:22:37Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T08:29:56Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; BOR-RU LIN; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-10-25T02:57:41Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; |Hsu C.-H; |Lin J.-K; |Hsu M.-M; |Ho Y.-F; |She T.-S; |JENG-YUH KO; |Lin J.-T; |Lin B.-R; |Wu M.-S; |Yu H.-S; |Jee S.-H; |Chen G.-S; |Chen T.-M; |Chen C.-A; |Lai M.-K; |Pu Y.-S; |Pan M.-H; |Wang Y.-J; |Tsai C.-C; |Hsieh C.-Y. |
| 臺大學術典藏 |
2021-11-18T04:58:19Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; Hsu C.-H; Lin J.-K; Hsu M.-M; Ho Y.-F; She T.-S; JENG-YUH KO; Lin J.-T; Lin B.-R; Wu M.-S; Yu H.-S; Jee S.-H; Chen G.-S; Chen T.-M; Chen C.-A; Lai M.-K; Pu Y.-S; Pan M.-H; Wang Y.-J; Tsai C.-C; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-11-15T07:48:43Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; Hsu C.-H; Lin J.-K; Hsu M.-M; Ho Y.-F; She T.-S; JENG-YUH KO; Lin J.-T; Lin B.-R; Wu M.-S; Yu H.-S; Jee S.-H; Chen G.-S; Chen T.-M; Chen C.-A; Lai M.-K; Pu Y.-S; Pan M.-H; Wang Y.-J; Tsai C.-C; Hsieh C.-Y. |
| 臺大學術典藏 |
2022-09-06T08:56:53Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 國家衛生研究院 |
2021-03-01 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
|
Tsai, HJ;Shiah, HS;Chang, JY;Su, WC;Chiang, NJ;Chen, LT |
| 國立成功大學 |
2021-03-1 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
|
Tsai;Hui-Jen;Shiah;Her-Shyong;Chang;Jang-Yang;Su;Wu-Chou;Chiang;Nai-Jung;Chen;Li-Tzong |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
|
Ansell P; Motwani M; Wong S; Yue H; Wang L; Reilly E; Afar D; Naumovski L; Ramanathan R.K.; Strickler J.H; LoRusso P; Salgia R; Kang Y.-K; Yen C.J; Chia-Chi Lin |
| 國立成功大學 |
2020 |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler, J.H.;LoRusso, P.;Salgia, R.;Kang, Y.-K.;Yen, C.J.;Lin, C.-C.;Ansell, P.;Motwani, Motwani M.;Wong, S.;Yue, H.;Wang, L.;Reilly, E.;Afar, D.;Naumovski, L.;Ramanathan, Ramanathan R.K. |
顯示項目 655311-655335 / 2312640 (共92506頁)
<< < 26208 26209 26210 26211 26212 26213 26214 26215 26216 26217 > >>
每頁顯示[10|25|50]項目
|
